Both talazoparib and veliparib, PARP inhibitors with greater PARP activity inhibition and trapping action, have recently received clinical approval for breast cancer treatment, enabling dosage reduction and improving clinical efficacy [17]. Here, PARP1 is linked to breast cancer.